Controlled heart attack restores quality of life
A unique procedure, which involves the use of alcohol to induce a controlled heart attack is restoring quality of life for a small number of patients.
Visitor information – Everything you need to know about visiting our sites.
A unique procedure, which involves the use of alcohol to induce a controlled heart attack is restoring quality of life for a small number of patients.
Clinicians world-wide now have stronger evidence to use when asking their atrial fibrillation patients to stop drinking.
Angela is one of the first patients to have an echocardiogram at Sandringham Hospital, after The Alfred expanded its services to Bayside.
A complex surgery to remove chronic blood clots from arteries in the lungs is giving Australians and New Zealanders a second chance.
When Petra Brosch’s heart stopped beating during a routine run on Elwood beach, it was the beginning of a journey that would see The Alfred’s specialists drawing on the latest in cutting-edge medicine to save her life. The 35-year-old was suffering irreparable heart failure that would see her rely on life support, then an artificial heart and ultimately organ transplant.
Queen’s Birthday weekend in 2016 is one Daniel Vizor will never forget. That was the weekend that, overnight, his life changed forever.
Patients being treated for heart rhythm disorders are commonly advised to avoid caffeine, however a new study suggests coffee and tea may be tolerated – and could even help manage an irregular heart rate.
A life-changing discovery in heart research has revealed a one-off procedure to treat a common condition can also reverse heart failure and eliminate the need for lifelong medication in some patients.
The Alfred is the first Australian hospital to take part in a global trial that could eliminate the need for open heart surgery in some patients suffering a common heart valve disease.
The Alfred's Director of Anaesthesia and Perioperative Medicine, Professor Paul Myles, and his team were today awarded Australian Trial of the Year for their worldwide study exploring the risks associated with aspirin and tranexamic acid (TXA).